Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure - Kasperova, Barbora Judita; Mraz, Milos; Svoboda, Petr; Hlavacek, Daniel; Kratochvilova, Helena; Modos, Istvan; Vrzackova, Nikola; Ivak, Peter; Janovska, Petra; Kobets, Tatyana; Mahrik, Jakub; Riecan, Martin; et al. (Cardiovascular diabetology, 2024)
Keywords: Adipose tissue; Adipose Tissue - drug effects; Adipose Tissue - metabolism; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Architects; Biomarkers - blood; Body fat; Body mass index; Cardiovascular disease; Cardiovascular diseases; Congestive heart failure; Coronary vessels; Cytokines; Data analysis; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Ejection fraction; Epicardial Adipose Tissue; Ether lipids; Female; Ferroptosis; Flow cytometry; Gene expression; Glucose; Health risks; Heart diseases; Heart failure; Heart Failure - drug therapy; Heart Failure - metabolism; Heart Failure - physiopathology; Heart transplantation; Heart transplants; Humans; Inflammation; Inflammation Mediators - metabolism; Lipid metabolism; Lymphocytes; Male; Metabolomics; Middle Aged; Mortality; Obesity; Oleic acid; Oxidative stress; Patients; Pericardium - drug effects; Pericardium - metabolism; Severity of Illness Index; Sodium; Sodium-glucose cotransporter; Sodium-glucose cotransporter 2 inhibitors; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Sodium-Glucose Transporter 2 Inhibitors - pharmacology; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Stroke Volume - drug effects; Treatment Outcome; Ventricular Function, Left - drug effects; United States--US; Germany; Heart failure; Ether lipids; Inflammation; Adipose tissue; Sodium-glucose cotransporter 2 inhibitors